Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile

Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile

January 13, 2014

Clinical efficacy observed in first 10 patients

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics(TM) for Rare Diseases

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics(TM) for Rare Diseases

January 13, 2014

CHESHIRE, Conn. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Moderna Therapeutics today announced an exclusive strategic agreement for the discovery and development of messenger RNA Therapeutics(TM) to treat rare diseases. Alexion is a global leader in the development and commercialization of breakthrough therapies for patients with severe and life-threatening rare diseases. Moderna is a pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a highly innovative treatment modality to enable the in vivo production of therapeutic proteins.

T2 Biosystems and Collaborators Announce Discovery of Novel Clot Structure Biology Enabled by T2HemoStat

T2 Biosystems and Collaborators Announce Discovery of Novel Clot Structure Biology Enabled by T2HemoStat

January 9, 2014

--T2HemoStat Detection of Novel Clot Behavior Could Direct Therapeutic Choices for Stroke and Heart Attack Victims--

Selventa Receives Patent for Extracting Knowledge From Biological Networks

Selventa Receives Patent for Extracting Knowledge From Biological Networks

January 7, 2014

CAMBRIDGE, MA-- Selventa today announced that it has been issued United States Patent, No. 8,594,941, which covers a system, method and apparatus for causal implication analysis in biological networks. The patent covers both reverse and forward causal reasoning, and, in particular, describes automated reasoning techniques that process networks of causal relationships to formulate hypotheses and evaluate those hypotheses against data sets of differential measurements.

Blend Therapeutics Appoints Richard Wooster, Ph.D., as Chief Scientific Officer

Blend Therapeutics Appoints Richard Wooster, Ph.D., as Chief Scientific Officer

January 6, 2014

WATERTOWN, MA – Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has appointed pharmaceutical industry veteran Richard Wooster, Ph.D., as Chief Scientific Officer. Dr. Wooster will be responsible for leading the Company’s research and development strategy and clinical operations as its lead drug candidates focused on oncology advance toward clinical development.

Eleven Biotherapeutics Files Registration Statement for Proposed Initial Public Offering

Eleven Biotherapeutics Files Registration Statement for Proposed Initial Public Offering

January 2, 2014

Cambridge, MA –Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced that it has filed a registration statement on Form S-­‐1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. All shares of the common stock in the offering will be sold by Eleven. The number of shares to be offered and the price range for the offering have not yet been determined.

Eleven Biotherapeutics Adds Biotech Industry Veterans to Management Team and Board

Eleven Biotherapeutics Adds Biotech Industry Veterans to Management Team and Board

January 2, 2014

Eleven Appoints Gregory D. Perry as Chief Financial and Business Officer, Daniel S. Lynch as Chairman of Company’s Board of Directors and Jane Pritchett Henderson as a Board Member

Eleven Biotherapeutics Establishes Scientific Advisory Board to Guide Ophthalmic Pipeline and Technology Development

Eleven Biotherapeutics Establishes Scientific Advisory Board to Guide Ophthalmic Pipeline and Technology Development

December 23, 2013

Cambridge, MA – Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has established a Scientific Advisory Board (SAB) to guide the Company’s core therapeutic and technologic approaches, including its ophthalmic pipeline and protein engineering platform. The members of the SAB include clinical and scientific experts in the areas of ocular disease (both front and back of the eye), immunology and cytokine biology and protein engineering.

Syros Pharmaceuticals Announces Publication of Important Scientific Studies Related to Company's Industry-Leading Gene Control Platform

Syros Pharmaceuticals Announces Publication of Important Scientific Studies Related to Company's Industry-Leading Gene Control Platform

December 18, 2013

- Cancer Cell paper demonstrates a road map to tumor dependencies in lymph node cancer from Super-Enhancer analysis -

- Nature Biotechnology paper describes novel ChemSeq technology, which allows for genome mapping of small molecules -

Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis

Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis

December 18, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene, has initiated a phase 2 clinical trial of sotatercept in patients with end stage renal disease on hemodialysis.